Development of a Vaccine against Escherichia coli Urinary Tract Infections
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Urinary tract infection (UTI) is the second most common infection in humans after those involving the respiratory tract. This results not only in huge annual economic costs, but in decreased workforce productivity and high patient morbidity. Most infections are caused by uropathogenic Escherichia coli (UPEC). Antibiotic treatment is generally effective for eradication of the infecting strain; however, documentation of increasing antibiotic resistance, allergic reaction to certain pharmaceuticals, alteration of normal gut flora, and failure to prevent recurrent infections represent significant barriers to treatment. As a result, approaches to prevent UTI such as vaccination represent a gap that must be addressed. Our laboratory has made progress toward development of a preventive vaccine against UPEC. The long-term research goal is to prevent UTIs in women with recurrent UTIs. Our objective has been to identify the optimal combination of protective antigens for inclusion in an effective UTI vaccine, optimal adjuvant, optimal dose, and optimal route of delivery. We hypothesized that a multi-subunit vaccine elicits antibody that protects against experimental challenge with UPEC strains. We have systematically identified four antigens that can individually protect experimentally infected mice from colonization of the bladder and/or kidneys by UPEC when administered intranasally with cholera toxin (CT) as an adjuvant. To advance the vaccine for utility in humans, we will group the individual antigens, all associated with iron acquisition (IreA, Hma, IutA, FyuA), into an effective combination to establish a multi-subunit vaccine. We demonstrated for all four vaccine antigens that antigen-specific serum IgG represents a strong correlate of protection in vaccinated mice. High antibody titers correlate with low colony forming units (CFUs) of UPEC following transurethral challenge of vaccinated mice. However, the contribution of cell-mediated immunity cannot be ruled out and must be investigated experimentally. We have demonstrated that antibodies bind to the surface of UPEC expressing the antigens. Sera from women with and without histories of UTI have been tested for antibody levels to vaccine antigens. Our results validate iron acquisition as a target for vaccination against UTI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucosal Immunization with Iron Receptor Antigens Protects against Urinary Tract Infection
Alteri, C. J., Hagan, E. C., Sivick, K. E., Smith, S. N., & Mobley, H. L. T. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000586 · Cited by 201
Self-citation
Cited by
Klein, R. D., & Hultgren, S. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0324-0 · Cited by 557
Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics
Timm, M. R., Russell, S. K., & Hultgren, S. J. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01092-4 · Cited by 190
Rapid growth and metabolism of uropathogenic Escherichia coli in relation to urine composition
Reitzer, L., & Zimmern, P. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-19 · Cited by 85
Structural insights into Cir-mediated killing by the antimicrobial protein Microcin V
Maurakis, S. A., O’Donnell, A. C., Botos, I., Ghirlando, R., Davies, B. W., & Buchanan, S. K. (2025) · Communications Biology · doi:10.1038/s42003-025-08846-7 · Cited by 3
Metadata
- Authors
- Mobley, H., & Alteri, C.
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2015-12-31
- Volume
- 5
- Issue
- 1
- Pages
- 1
- ISSN
- 2076-0817 (ISSN-L)
- OpenAlex
- W2211496198
- Cited by
- 81
- References
- 1
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a Vaccine against Escherichia coli Urinary Tract Infections. https://app.cochat.ai/papers/10.3390/pathogens5010001
- The paper
- Mobley, H., & Alteri, C. (2015). Development of a Vaccine against Escherichia coli Urinary Tract Infections. Pathogens. https://doi.org/10.3390/pathogens5010001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.